• vcard
  • Education
    • J.D., magna cum laude, University of Notre Dame Law School, 2011, Articles Editor, Notre Dame Law Review
    • B.A., Wesleyan University, 2008

Chris Simpson counsels clients regarding a wide range of transactional and corporate law matters. With a particular focus on the life sciences space, Chris advises clients across the spectrum – from growth-oriented companies to venture and growth equity funds – on significant mergers, acquisitions, strategic collaborations and similar transactions as well as day to day operative and commercial matters.

Corporate & Transactional

Chris represents and advises public and private companies in a variety of industries in mergers and acquisitions, securities law compliance issues, equity financings and general corporate governance work.

Life Sciences

Chris advises life sciences companies from start-up stage to public companies on various corporate matters including negotiating investments, mergers and acquisitions, strategic collaborations and joint ventures and public offerings. Chris also assists life sciences companies with day-to-day corporate and business development strategies.

Venture Capital and Growth Equity

Chris counsels venture capital and growth equity funds in connection with their debt and equity financing investments in private companies.

Cross-Border Experience

A large portion of Chris’ experience has involved cross-border transactions in the life sciences space, including cross-border acquisitions, financings, joint ventures and collaborations

Before Polsinelli, Chris practiced at Choate, Hall & Stewart, LLP in Boston Massachusetts.

  • Representation of publicly-traded pharmaceutical company in $1 billion+ acquisition of drug-development company.

  • Representation of multi-national contract drug manufacturer in acquisition of laboratory spun off from a major US university.

  • Representation of a pre-commercial drug development company in a number of cross-border research and licensing collaborations with non-US companies and universities.

  • Representation of a Swiss medical device company in its sale to a US publicly-traded company.

  • Representation of numerous life science and technology companies in seed, Series A and successive rounds of venture capital and growth equity financings.

  • Representation of leading venture capital firm in financing of life science companies.

  • Representation of leading growth equity firm in financing of healthcare IT companies.

  • Representation of private equity-backed home health and hospice company in multiple roll-up acquisitions.

  • Representation of biotechnology company in a variety of commercial matters, including manufacturing agreements, license agreements and sponsored research agreements.